gatm Antibody

What is GATM protein and what is its biological significance?

GATM (glycine amidinotransferase) is a key enzyme that catalyzes the transfer of the amidino group from L-arginine to glycine, forming guanidinoacetate - the first and rate-limiting step in creatine biosynthesis. GATM is predominantly expressed in kidney and pancreas in adults and provides creatine as a source for ATP generation in tissues with high energy demands, particularly skeletal muscle, heart, and brain. GATM deficiency in early infancy causes neurodevelopmental delay, highlighting its critical role in development .

The enzyme, also known as AGAT or transamidinase, catalyzes reactions that yield guanidine derivatives from various acceptor metabolites including glycine, beta-alanine, gamma-aminobutyric acid (GABA), and taurine. Its primary function is generating guanidinoacetate, which is subsequently methylated by GAMT to form creatine .

What are the optimal applications for commercially available GATM antibodies?

Current GATM antibodies have been validated for multiple research applications with specific recommended dilutions:

For Proteintech GATM antibody (12801-1-AP):

For Bio-Techne GATM Antibody (NBP1-89211):

These applications have been validated through multiple published studies, with each antibody demonstrating reliable reactivity for human samples, and variable cross-reactivity with mouse and rat samples .

What tissue samples are most appropriate as positive controls for GATM antibody validation?

Based on GATM's known expression pattern, the following tissues serve as reliable positive controls:

• Human kidney tissue

• Mouse kidney tissue

• Rat kidney tissue

• Human pancreas tissue (normal and cancerous)

• Rat pancreas tissue

Western blot analysis has confirmed positive detection in all these tissues, with the protein appearing at the expected molecular weight of 48 kDa. For immunohistochemistry applications, human pancreatic cancer tissue has been specifically validated as a positive control .

What are the optimal antigen retrieval methods for GATM immunohistochemistry?

For optimal GATM detection in paraffin-embedded tissues, specific antigen retrieval conditions are recommended:

• Primary recommendation: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

For Bio-Techne's NBP1-89211 antibody specifically, Heat-Induced Epitope Retrieval (HIER) at pH 6.0 is recommended for IHC-Paraffin applications .

The choice between these methods may depend on tissue type, fixation conditions, and the specific antibody clone being used. Researchers should validate both methods with their specific samples to determine optimal conditions for their experimental system.

How can researchers differentiate between mitochondrial and cytoplasmic GATM staining patterns?

GATM has been demonstrated to localize primarily to mitochondria, as shown by immunofluorescence studies with the NBP1-89211 antibody in human RH-30 cells . To differentiate between mitochondrial and potential cytoplasmic staining:

• Use co-localization studies with established mitochondrial markers

• Employ subcellular fractionation followed by Western blotting

• Utilize super-resolution microscopy for precise localization

• Compare staining patterns with both N-terminal and C-terminal targeting GATM antibodies

For immunofluorescence applications, PFA/Triton X-100 fixation and permeabilization is specifically recommended to maintain mitochondrial morphology while allowing antibody access .

What strategies should be employed to optimize Western blot detection of GATM?

For optimal Western blot detection of GATM:

• Sample preparation: Tissue homogenization should be performed in buffers containing protease inhibitors to prevent degradation.

• Loading controls: For cross-tissue comparisons, use appropriate loading controls for each tissue type.

• Antibody dilution: Begin with the mid-range of recommended dilutions (1:1000 for Proteintech antibody or 0.2 μg/ml for Bio-Techne antibody) and adjust based on signal intensity.

• Expected molecular weight: GATM has a calculated and observed molecular weight of 48 kDa.

• Positive controls: Include kidney or pancreas tissue as positive controls in each experiment.

When troubleshooting weak signals, consider extended antibody incubation times (overnight at 4°C) or more sensitive detection systems .

How can GATM antibodies be used to study creatine metabolism disorders?

GATM antibodies provide valuable tools for investigating creatine metabolism disorders:

• Expression analysis: Western blotting can quantify GATM protein levels in patient-derived samples compared to controls.

• Tissue distribution studies: IHC or IF can map GATM expression patterns in affected tissues.

• Functional correlations: Combining antibody-based protein detection with enzymatic activity assays can reveal structure-function relationships.

• Animal models: GATM antibodies can validate disease models by confirming altered expression or localization patterns.

Researchers studying creatine deficiency syndromes should particularly focus on kidney, pancreas, and brain tissues, where GATM expression and function are most relevant to pathophysiology .

What considerations are important when using GATM antibodies in developmental studies?

When studying GATM during development:

• Developmental timing: GATM expression changes during development, requiring time-point specific positive controls.

• Species considerations: Confirm antibody cross-reactivity with developmental model species (validated for human, mouse, and rat with variable homology).

• Tissue-specific expression: GATM expression is regulated differently across tissues during development.

• Fixation optimization: Developing tissues may require modified fixation protocols for optimal antibody penetration.

GATM deficiency causes neurodevelopmental delay, making developmental studies particularly relevant to understanding its role in normal development and pathological conditions .

What are the critical validation steps for confirming GATM antibody specificity?

Comprehensive validation of GATM antibodies should include:

• Western blot analysis: Confirm single band at expected molecular weight (48 kDa).

• Positive control tissues: Validate using known GATM-expressing tissues (kidney, pancreas).

• Peptide competition: Perform pre-absorption with immunizing peptide to confirm specificity.

• Cross-species reactivity: Test predicted cross-reactivity with mouse (93% homology) and rat (91% homology) samples.

• Knockout/knockdown controls: Where available, use GATM-deficient samples as negative controls.

Each validation step should be documented with appropriate controls and quantitative analysis to ensure reproducibility .

How should researchers interpret variations in GATM staining intensity across different tissues?

Variations in GATM staining intensity across tissues require careful interpretation:

• Biological variation: GATM is predominantly expressed in kidney and pancreas, with lower expression in other tissues.

• Technical considerations: Different tissue types may require optimization of antigen retrieval and antibody concentration.

• Quantification methods: Use digital image analysis with tissue-specific controls for objective comparisons.

• Validation approaches: Confirm expression patterns using orthogonal methods (qPCR, proteomics).

When comparing GATM expression across tissues, researchers should standardize protocols and include tissue-specific positive and negative controls to account for matrix effects .

How can machine learning approaches enhance antibody-antigen binding prediction for GATM studies?

Recent advances in machine learning offer promising approaches for GATM antibody research:

• Library-on-library screening: Machine learning models can predict target binding by analyzing many-to-many relationships between antibodies and antigens.

• Active learning strategies: These approaches can significantly reduce experimental costs by starting with a small labeled subset of data and iteratively expanding the dataset.

• Performance improvements: The best algorithms reduced the number of required antigen mutant variants by up to 35% and accelerated the learning process by 28 steps compared to random baseline.

• Out-of-distribution prediction: These models address the challenge of predicting interactions when test antibodies and antigens are not represented in training data.

These computational approaches are particularly valuable for optimizing experimental design in GATM binding studies, reducing costs while improving predictive accuracy .

What are the methodological considerations for multiplexed immunofluorescence studies involving GATM?

For multiplexed immunofluorescence studies involving GATM:

• Antibody compatibility: Select primary antibodies raised in different host species to avoid cross-reactivity.

• Fluorophore selection: Choose fluorophores with minimal spectral overlap and appropriate brightness for the expected GATM expression level.

• Sequential staining: Consider sequential rather than simultaneous staining to minimize cross-reactivity.

• Controls: Include single-stained controls and secondary-only controls to identify bleed-through and non-specific binding.

• Imaging parameters: Optimize exposure settings for each channel individually before multiplexed imaging.

Given GATM's mitochondrial localization, co-staining with mitochondrial markers can provide valuable insights into its specific subcellular distribution patterns .

How can researchers address inconsistent GATM staining patterns in immunohistochemistry?

When encountering inconsistent GATM staining in IHC:

• Fixation variables: Standardize fixation time, temperature, and fixative composition.

• Antigen retrieval optimization: Compare recommended methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0).

• Antibody titration: Test multiple dilutions within the recommended range (1:20-1:200 for Proteintech antibody or 1:500-1:1000 for Bio-Techne antibody).

• Blocking optimization: Adjust blocking conditions to reduce background while maintaining specific signal.

• Detection system sensitivity: Consider amplification systems for tissues with lower GATM expression.

For human pancreatic cancer tissue specifically, the Proteintech antibody has been validated with TE buffer pH 9.0 antigen retrieval .

What strategies can resolve discrepancies between Western blot and immunohistochemistry results for GATM?

Discrepancies between Western blot and IHC results for GATM may arise from several factors:

• Epitope accessibility: Protein denaturation in Western blot versus partial preservation in IHC may affect epitope recognition.

• Sample heterogeneity: Western blot homogenizes tissue, while IHC preserves spatial information that may reveal cell-specific expression patterns.

• Sensitivity differences: Western blot may detect low expression levels not visible in IHC.

• Protocol optimization: Each method requires independent optimization for GATM detection.

To resolve such discrepancies:

• Validate with multiple antibody clones targeting different GATM epitopes

• Perform subcellular fractionation to enrich for mitochondrial proteins

• Use complementary methods (qPCR, mass spectrometry) to confirm expression patterns

• Consider microdissection to analyze specific regions identified in IHC for Western blot analysis